|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CYR61 |
Gene summary for CYR61 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CYR61 | Gene ID | 3491 |
| Gene name | cellular communication network factor 1 | |
| Gene Alias | CYR61 | |
| Cytomap | 1p22.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | O00622 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3491 | CYR61 | GSM4909285 | Human | Breast | IDC | 3.53e-04 | -5.32e-01 | 0.21 |
| 3491 | CYR61 | GSM4909286 | Human | Breast | IDC | 9.08e-11 | -6.13e-01 | 0.1081 |
| 3491 | CYR61 | GSM4909288 | Human | Breast | IDC | 5.37e-03 | -5.95e-01 | 0.0988 |
| 3491 | CYR61 | GSM4909290 | Human | Breast | IDC | 1.99e-06 | -5.52e-01 | 0.2096 |
| 3491 | CYR61 | GSM4909293 | Human | Breast | IDC | 1.46e-14 | -6.82e-01 | 0.1581 |
| 3491 | CYR61 | GSM4909294 | Human | Breast | IDC | 9.17e-15 | -6.41e-01 | 0.2022 |
| 3491 | CYR61 | GSM4909297 | Human | Breast | IDC | 1.98e-08 | -5.33e-01 | 0.1517 |
| 3491 | CYR61 | GSM4909301 | Human | Breast | IDC | 1.68e-03 | -4.69e-01 | 0.1577 |
| 3491 | CYR61 | GSM4909304 | Human | Breast | IDC | 1.62e-07 | -5.51e-01 | 0.1636 |
| 3491 | CYR61 | GSM4909307 | Human | Breast | IDC | 3.34e-18 | -7.11e-01 | 0.1569 |
| 3491 | CYR61 | GSM4909308 | Human | Breast | IDC | 3.78e-15 | -6.82e-01 | 0.158 |
| 3491 | CYR61 | GSM4909311 | Human | Breast | IDC | 6.70e-20 | -6.85e-01 | 0.1534 |
| 3491 | CYR61 | GSM4909315 | Human | Breast | IDC | 8.71e-17 | -6.96e-01 | 0.21 |
| 3491 | CYR61 | GSM4909316 | Human | Breast | IDC | 4.40e-07 | -7.37e-01 | 0.21 |
| 3491 | CYR61 | GSM4909317 | Human | Breast | IDC | 4.92e-09 | -5.86e-01 | 0.1355 |
| 3491 | CYR61 | GSM4909318 | Human | Breast | IDC | 8.10e-06 | -7.99e-01 | 0.2031 |
| 3491 | CYR61 | GSM4909319 | Human | Breast | IDC | 7.66e-25 | -7.10e-01 | 0.1563 |
| 3491 | CYR61 | GSM4909320 | Human | Breast | IDC | 3.71e-10 | -7.58e-01 | 0.1575 |
| 3491 | CYR61 | GSM4909321 | Human | Breast | IDC | 3.68e-03 | -3.19e-01 | 0.1559 |
| 3491 | CYR61 | ctrl6 | Human | Breast | Precancer | 2.05e-04 | 5.48e-01 | -0.0061 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CYR61 | SNV | Missense_Mutation | c.490N>A | p.Asp164Asn | p.D164N | O00622 | protein_coding | tolerated(0.14) | benign(0.214) | TCGA-A8-A090-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CYR61 | SNV | Missense_Mutation | c.685N>C | p.Cys229Arg | p.C229R | O00622 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| CYR61 | SNV | Missense_Mutation | c.769N>C | p.Glu257Gln | p.E257Q | O00622 | protein_coding | tolerated(0.9) | benign(0.014) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| CYR61 | insertion | Nonsense_Mutation | novel | c.622_623insCCGCGCTCGCCCCGGGCTACTCCTGCGCGCCACAATG | p.Lys208ThrfsTer13 | p.K208Tfs*13 | O00622 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CYR61 | SNV | Missense_Mutation | c.796N>T | p.Ile266Phe | p.I266F | O00622 | protein_coding | deleterious(0.01) | benign(0.378) | TCGA-EK-A3GN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| CYR61 | SNV | Missense_Mutation | novel | c.892T>C | p.Phe298Leu | p.F298L | O00622 | protein_coding | tolerated(0.61) | benign(0.006) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| CYR61 | SNV | Missense_Mutation | c.848N>A | p.Gly283Asp | p.G283D | O00622 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| CYR61 | SNV | Missense_Mutation | novel | c.767N>A | p.Pro256His | p.P256H | O00622 | protein_coding | deleterious(0.02) | possibly_damaging(0.828) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CYR61 | SNV | Missense_Mutation | novel | c.767N>A | p.Pro256His | p.P256H | O00622 | protein_coding | deleterious(0.02) | possibly_damaging(0.828) | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CYR61 | SNV | Missense_Mutation | c.1010N>A | p.Cys337Tyr | p.C337Y | O00622 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0R6-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |